Ricerca Biosciences appoints drug safety director
Douglas Fuhrer has right skills to guide preclinical drug development strategy
Fuhrer has more than 12 years of experience directing teams of scientists and technicians in large pharmaceutical companies, biotech organisations and CROs. His training and experience includes applied animal investigation skills, serving as a study director of toxicology and safety pharmacology Good Laboratory Practice (GLP) studies and completing multiple INDs and non-clinical programmes supporting clinical development. His expertise lies within many therapeutic areas including anti-infectives, cancer, immune regulation, diabetes, CNS, prostate enlargement and hepatitis C.
‘Doug possesses the experience and insights necessary to guide our preclinical drug development strategies,’ said Michael Placke, senior vice president and general manager of Ricerca’s Concord, Ohio, drug development operations.
You may also like
Packaging
How pharma packaging manufacturers role is evolving: the case of extractables testing
As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma